P14-04. HIV-SELECTEST EIA and rapid test: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies

por Khurana, S, Norris, PJ, Busch, MP, Mlisana, K, Salim, AK, Hunter, E, Golding, H
Publicado 2009

P09-04. Charge changes in the alpha2-helix in the C3 region of the HIV-1 subtype C envelope mediate neutralization escape

por Moore, PL, Ranchobe, N, Lambson, B, Gray, E, Mlisana, K, Karim, S Abdool, Williamson, C, Gnanakaran, S, Morris, L
Publicado 2009

P04-06. Evolution of an anti-MPER gp41 antibody response that mediates broad HIV-1 cross-neutralization

por Gray, E, Moore, P, Ranchobe, N, Abrahams, M, Madiga, M, Mlisana, K, Abdool-Karim, S, Williamson, C, Morris, L
Publicado 2009

HIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trials

por Volk, JE, Hessol, NA, Gray, GE, Kublin, JG, Churchyard, G, Mlisana, K, Nchabeleng, M, Buchbinder, SP, Bekker, L
Publicado 2012

P13-05. Factors associated with pregnancy during the HVTN 503/Phambili trial, a phase IIB HIV trial of the Merck Ad-5 multi-clade HIV vaccine

por Latka, M, Grey, G, Fielding, K, Bekker, L, Mlisana, K, Nchabeleng, M, DeBruin, G, Allen, M, Kublin, J, Churchyard, G
Publicado 2009

Increased differentiation associates with decreased polyfunctionality for HIV but not CMV-specific CD8+ T cell responses

por Riou, C, Abrahams, M, Mlisana, K, Koup, R, Roederer, M, Karim, S Abdool, de Bruyn, G, Williamson, C, Gray, CM, Burgers, WA
Publicado 2012

P14-02. Social impact events in Phambili, the first phase 2B HIV vaccine trial in South Africa

por Allen, MA, Gray, G, Churchyard, G, Bekker, L, Nchabeleng, M, Mlisana, K, Metch, B, Moodie, Z, Roux, S, Mathebula, M, Bennie, T, Kublin, J
Publicado 2009

TB testing in HIV-positive patients prior to antiretroviral treatment

por Spooner, E., Reddy, S., Ntoyanto, S., Sakadavan, Y., Reddy, T., Mahomed, S., Mlisana, K., Dlamini, M., Daniels, B., Luthuli, N., Ngomane, N., Kiepiela, P., Coutsoudis, A.
Publicado 2022

P14-07. Offering new prevention modalities in HIV vaccine trials: experience with male circumcision in the Phambili trial

por de Bruyn, G, Mlisana, K, Metch, B, Churchyard, G, Nchabeleng, M, Bekker, L, Roux, S, Naicker, N, Latka, M, Corey, L, Kublin, J, Gray, G
Publicado 2009

Beneficial HLA-mediated viral polymorphisms on the transmitted virus additively influence disease progression in HIV-1, subtype C infection

por Ntale, RS, Chopera, DR, Ngandu, NK, Abrahams, M, Debra, A, Mlotswa, M, Werner, L, Woodman, Z, Mlisana, K, Karim, S Abdool, Gray, CM, Williamson, C
Publicado 2012

P15-13. HVTN 503(Phambili) trial discontinuation of enrolment/vaccination: the impact on trial participant attitudes to vaccine trials and scientific research

por Mark, D, Middelkoop, K, Roux, S, Gray, G, Mlisana, K, Nchabaleng, M, Churchyard, G, De Bruyn, G, Latka, M, Magagula, D, Kublin, J, Allen, M, Bekker, L
Publicado 2009

P15-08. Did unblinding affect HIV risk behaviour and risk perception in the HVTN503/Phambili study?

por Gray, GE, Bekker, L, Churchyard, G, Nchabeleng, M, Mlisana, K, de Bruyn, G, Roux, S, Mathebula, M, Latka, M, Bennie, T, Metch, B, Moodie, Z, Allen, M, Eaton, N, Kublin, J
Publicado 2009

Killer-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women

por Naranbhai, V., de Assis Rosa, D., Werner, L., Moodley, R., Hong, H., Kharsany, A., Mlisana, K., Sibeko, S., Garrett, N., Chopera, D., Carr, W. H., Abdool Karim, Q., Hill, A. V. S., Abdool Karim, S. S., Altfeld, M., Gray, C. M., Ndung’u, T.
Publicado 2016